- Around 500 people were diagnosed with bone sarcoma in 2012 in the UK, that’s around 1 person every day.
- Bone sarcoma accounts for 0.1% of all new cases in the UK (2012).
- In men, there were around 300 cases of bone sarcoma diagnosed in the UK in 2012.
- In women, there were around 200 cases of bone sarcoma diagnosed in the UK in 2012.
- Bone sarcoma peopleis most common in older children and teenagers, and older people.
- 3 in 20 (15%) cases of bone sarcoma are diagnosed in people aged 75 and over.
- More than a quarter (28%) of bone sarcomas occur in children, teenagers and young adults (up to age 24).
- Malignant bone tumours account for 4% of childhood cancers and 5% of teenage and young adult cancers.
- Bone sarcoma incidence rates have remained stable overall in Great Britain since the late-1970s, though this trend includes a decrease followed by an increase. This increase probably reflects improved diagnostic techniques and reporting rather than a true increase in incidence, however.
- Over the last decade, bone sarcoma incidence rates have remained stable in the UK.
Bone sarcoma statistics
New cases of bone sarcoma, 2012, UK
Deaths from bone sarcoma, 2012, UK
Survive bone sarcoma for 5 or more years, 2001-2005, England
Preventable cases of bone sarcoma, UK
- In the UK there were around 250 deaths from bone sarcoma in 2012, nearly 5 people every week.
- Around a quarter of bone sarcoma deaths occur in people aged 75 and over, and a further quarter occur in people under 30.
- Bone sarcoma death rates in the UK have remained stable over the last decade.
- Less than 1% of bone sarcoma cases each year in the UK are linked to major lifestyle and other risk factors.
- A person’s risk of developing bone sarcoma depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- Evidence on bone sarcoma risk factors is limited, mainly because this cancer is relatively rare and comprises many subtypes.
- Some forms of ionising radiation cause bone sarcoma.
- Previous cancer treatment, larger body size, and certain medical conditions may relate to higher bone sarcoma risk.
- ‘Two-week wait’ standards are met by all countries, ‘31-day wait’ is met by all but Northern Ireland and Wales, and ’62 day wait’ is not met by any country for sarcoma.
The latest statistics for bone sarcoma in the UK are; incidence 2012, and mortality 2012. Limited survival data are published.
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Overall, the evidence on bone sarcoma risk factors is limited, mainly because of the relative rarity and diversity of this group of cancers. Studies which group together different morphological subtypes of bone sarcoma may be confounded if those subtypes have differing aetiologies. Where available, evidence from studies which define bone sarcomas by tumour morphology are cited; if studies define by ICD-9 or ICD-10 anatomical site only this is noted.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Bone sarcoma is part of the group 'Sarcoma' for cancer waiting times data. Codes vary per country but broadly include: bone and articular cartilage, Kaposi sarcoma, retroperitoneum and peritoneum, other connective and soft tissue, secondary cancers of retroperitoneum and peritoneum, secondary cancers of bone and bone marrow.
You are welcome to reuse this Cancer Research UK statistics content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.